RecruitingPHASE1, PHASE2NCT07262619
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eikon Therapeutics
- Principal Investigator
- Nilou Mobashery, MDEikon Therapeutics, Inc.
- Intervention
- EIK1005(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (10)
- Morristown Medical Center, Morristown, New Jersey, United States
- Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- GenesisCare North Shore (Oncology), Saint Leonards, New South Wales, Australia
- Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia
- Grampians Health, Ballarat, Victoria, Australia
- Chris O'Brien Lifehouse (Sydney Cancer Centre), Camperdown, Victoria, Australia
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital, Frankston, Victoria, Australia
- Peninsula and Southeast Oncology (PASO) Medical, Frankston, Victoria, Australia
- Health New Zealand, Wellington, New Zealand
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07262619 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- ACTIVE NOT RECRUITINGNCT07448493Local Treatment Strategies for Brain Metastases of Gastric and Esophageal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
- RECRUITINGPHASE2NCT06808971Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJCancer Institute and Hospital, Chinese Academy of Medical Sciences
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →